Late-breaking data presented from a Phase 2a trial … [Read more...] about Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Archives for October 2019
Presentation: Phase 2 Celiac Disease Data from UEG Week 2019
View Presentation Here … [Read more...] about Presentation: Phase 2 Celiac Disease Data from UEG Week 2019